Trial Profile
A Combination Study of Flotetuzumab and MGA012 (an anti-PD-1 monoclonal antibody) in Patients with Acute Myeloid-Leukaemia (AML)
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 08 May 2020
Price :
$35
*
At a glance
- Drugs Flotetuzumab (Primary) ; Retifanlimab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors MacroGenics
- 05 May 2020 According to an MacroGenics media release, the has stopped enrollment in an ex-U.S and this decision was not due to any safety finding or lack of activity and the company plans to resume the study in the U.S. in the future.
- 05 May 2020 Status changed from recruiting to suspended, according to a MacroGenics media release.
- 10 Dec 2019 Trial design released in the 61st Annual Meeting and Exposition of the American Society of Hematology.